Key facts
- Numerion Labs’s last known valuation is $981.0M (Mar 2026).
- It has raised $245.5M across 1 recorded rounds; the latest was Early Stage VC ($19.8M) in Mar 2026.
- Notable investors include Y Combinator, Creative Destruction Lab, Khosla Ventures, Draper Associates, University of Toronto — 34 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 34 names
- ·Watchlist + deal alerts for Numerion Labs
Funding rounds
1 roundsAbout Numerion Labs
Operator of an artificial intelligence-based biotechnology company intended to help invent new potential medicines for disease targets. The company's technology helps in drug hit discovery, binding affinity prediction, and toxicity detection, enabling scientists to discover small molecules for the treatment and investigation of human diseases.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2012
- Employees
- 18
- Website
- numerionlabs.ai/
- Ownership
- Privately Held (backing)
Numerion Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Numerion Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Numerion Labs in its N-PORT filings yet. We sweep new filings monthly.